Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice

Meng Du,Xiaojing Wang,Lin Yuan,Bing Liu,Xiaoxiang Mao,Dandan Huang,Liu Yang,Kun Huang,Fengxiao Zhang,Yan Wang,Xi Luo,Cheng Wang,Jiangtong Peng,Minglu Liang,Dan Huang,Kai Huang
DOI: https://doi.org/10.1016/j.jhep.2020.07.030
IF: 25.7
2020-12-01
Journal of Hepatology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background &amp; Aims</h3><p>The Nuclear Factor of Activated T-cells (NFAT) family was first recognized to play an important role in the differentiation of T cells, but has since been shown to regulate multiple pathophysiological processes. However, whether it is involved in the pathogenesis of nonalcoholic steatohepatitis (NASH) remains unknown.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Hepatic NFATc expression and localization were analysed in C57BL/6 mice on a methionine-choline-deficient (MCD) diet, as well as in samples from non-alcoholic fatty liver disease (NAFLD) patients. Gain- or loss-of-function approaches were used to investigate the role of NFATc4 in NASH.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>NFATc4 translocates from the cytoplasm to the nucleus in hepatocytes of both humans and rodents with NASH. NFATc4 knockdown (KD) resulted in decreased hepatic steatosis, inflammation and fibrosis during NASH progression. Mechanistically, we found that activated NFATc4 directly bound to peroxisome proliferator-activated receptor α (PPARα) in the nucleus and negatively regulated its transcriptional activity, thereby impairing the hepatic fatty acid oxidation (FAO) pathway and increasing lipid deposition in the liver. Moreover, NFATc4 activation increased the production and secretion of osteopontin (OPN) from hepatocytes, which subsequently enhanced the macrophage-mediated inflammatory response and hepatic stellate cell (HSC)-mediated fibrosis progression via paracrine signalling.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Hepatic NFATc4 activation accelerates the progression of NASH by suppressing PPARα signalling and increasing OPN expression. Genetic or pharmacological inhibition of NFATc4 may have potential for future therapy of NASH.</p>
gastroenterology & hepatology
What problem does this paper attempt to address?
The problem this paper attempts to address is the role of nuclear factor of activated T-cells (NFATc4) in the pathogenesis of non-alcoholic steatohepatitis (NASH). Specifically, the researchers explored the role of NFATc4 in the progression of NASH and attempted to alleviate NASH symptoms by inhibiting NFATc4. ### Background and Objective Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with some patients progressing to non-alcoholic steatohepatitis (NASH). NASH is characterized by hepatocyte ballooning and lobular inflammation, which can lead to liver fibrosis and cirrhosis. Although there have been some studies on the pathogenesis of NAFLD, effective pharmacological treatments are still lacking. ### Methods 1. **Animal Experiments**: Using C57BL/6 mice and db/db mice, NASH was induced by a methionine-choline deficient diet (MCD). 2. **Human Sample Analysis**: Analyzing liver tissue samples from NAFLD patients. 3. **Gene Manipulation**: Knockdown of NFATc4 expression via recombinant adeno-associated virus (rAAV)-mediated shRNA. 4. **Molecular Biology Techniques**: Including immunofluorescence, Western blot, qRT-PCR, chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA), etc. ### Main Results 1. **Nuclear Translocation of NFATc4**: In hepatocytes of NASH mice and patients, NFATc4 translocated from the cytoplasm to the nucleus. 2. **Effect of NFATc4 Knockdown**: NFATc4 knockdown significantly alleviated MCD diet-induced NASH symptoms in mice, including hepatic steatosis, inflammation, and fibrosis. 3. **Mechanistic Study**: Activated NFATc4 directly binds to peroxisome proliferator-activated receptor α (PPARα), negatively regulating its transcriptional activity, thereby inhibiting the hepatic fatty acid oxidation (FAO) pathway and increasing lipid deposition. Additionally, NFATc4 activation increased the production and secretion of osteopontin (OPN), enhancing macrophage-mediated inflammatory responses and hepatic stellate cell (HSC)-mediated fibrogenesis through paracrine signaling. ### Conclusion Activation of NFATc4 in hepatocytes accelerates the progression of NASH by inhibiting the PPARα signaling pathway and increasing OPN expression. Therefore, genetic or pharmacological inhibition of NFATc4 may become a potential strategy for future NASH treatment.